LGALS3 and acute myeloid leukemia: Patients with AML with higher LGALS3 mRNA expression had higher primary refractory rates to chemotherapy, lower complete remission (CR) rates and shorter overall survival (OS) compared to those with lower LGALS3 mRNA expression.